Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07519655 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
NCT07519655 is a Phase 1 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 250 participants.
The verdict
NCT07519655, a Phase 1 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
Study Summary
This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer. The study includes adult participants who have advanced cancers that cannot be removed by surgery or have spread to other parts of the body. These cancers include non-small cell lung cancer, esophageal squamous cell cancer, and melanoma. The study has two parts: In the first part, small groups of participants receive increasing doses of the study medicine. This helps researchers find a dose that is safe and suitable for further testing. Once a suitable dose is identified, the second part enrolls more participants with specific cancer types to better understand the safety of the medicine and whether it shows signs of helping control the cancer. Participants receive the study medicine through regular treatment cycles and are closely monitored for side effects and how their cancer responds. The information from this study will help researchers decide whether PF-08046033 should be studied further in later-stage clinical trials.
Interventions
- DRUG PF-08046033
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-04-08 |
| Est. Completion | 2029-07-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07519655
The ClinicalTrials.gov registry entry for NCT07519655 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-08046033 is the first listed.
NCT07519655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07519655 about?
NCT07519655 is a clinical study titled "Phase 1 Study of PF-08046033 in Advanced Solid Tumors". This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer. The study includes ...
What is the current status of trial NCT07519655?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2026-04-08. Estimated completion is 2029-07-14.
What interventions are being tested in trial NCT07519655?
The interventions under investigation include: PF-08046033 (DRUG).
Who is sponsoring clinical trial NCT07519655?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.